日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. TNFRSF4 (INCAGN-1949 Biosimilar) Recombinant Monoclonal Antibody

TNFRSF4 (INCAGN-1949 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA023981MB10HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    TNFRSF4(INCAGN-1949 Biosimilar Antibody)重組單克隆抗體是一種專為科研用途開發(fā)的生物制劑，其靶點為腫瘤壞死因子受體超家族成員4（TNFRSF4），該受體在免疫調(diào)節(jié)、炎癥反應(yīng)及腫瘤微環(huán)境調(diào)控中具有重要作用。本產(chǎn)品通過基因工程技術(shù)在哺乳動物細(xì)胞表達(dá)系統(tǒng)中重組表達(dá)，經(jīng)多步純化工藝獲得高純度、高特異性的單克隆抗體，可滿足多種實驗需求。 該抗體采用人源化或鼠源單克隆抗體結(jié)構(gòu)設(shè)計，具有與天然配體高親和力結(jié)合的特性，能特異性識別并結(jié)合TNFRSF4胞外結(jié)構(gòu)域，從而調(diào)控下游信號通路活性。在體外實驗中，可用于檢測細(xì)胞表面受體表達(dá)、分析亞細(xì)胞定位、驗證蛋白表達(dá)水平，以及ELISA定量檢測樣本中的可溶性受體含量。在細(xì)胞功能研究中，該抗體可通過激活或阻斷TNFRSF4信號，探究其在T細(xì)胞活化、B細(xì)胞增殖、巨噬細(xì)胞極化等免疫過程中的調(diào)控機制，為自身免疫性疾病、腫瘤免疫治療等領(lǐng)域的基礎(chǔ)研究提供關(guān)鍵工具。 產(chǎn)品嚴(yán)格遵循科研試劑質(zhì)量控制標(biāo)準(zhǔn)，經(jīng)SDS-PAGE和SEC-HPLC驗證純度大于95%，內(nèi)毒素含量低于0.1 EU/μg，確保實驗結(jié)果的準(zhǔn)確性與可重復(fù)性。每批次產(chǎn)品均提供詳細(xì)的質(zhì)檢報告，包括抗體濃度、親和力常數(shù)、特異性驗證數(shù)據(jù)等關(guān)鍵參數(shù)。該抗體推薦用于細(xì)胞培養(yǎng)、組織切片染色、蛋白質(zhì)相互作用分析某些實驗場景，為深入解析TNFRSF4的生物學(xué)功能及相關(guān)疾病機制提供可靠的研究支持。
  • Uniprot No.：
  • 基因名：
  • 別名：
    INCAGN 01949 research-grade biosimilar; INCAGN 1949 research-grade biosimilar ;TNFRSF4 antibody; TXGP1L antibody; Tumor necrosis factor receptor superfamily member 4 antibody; ACT35 antigen antibody; OX40L receptor antibody; TAX transcriptionally-activated glycoprotein 1 receptor antibody; CD antigen CD134 antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human TNFRSF4 protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價

靶點詳情

  • 功能：
    Receptor for TNFSF4/OX40L/GP34. Is a costimulatory molecule implicated in long-term T-cell immunity.; (Microbial infection) Acts as a receptor for human herpesvirus 6B/HHV-6B.
  • 基因功能參考文獻：
    1. High OX40 expression in Ovarian carcinoma is correlated with chemosensitivity and improved recurrence free survival in Ovarian carcinoma . Patients might therefore benefit from a second line therapy. PMID: 29661166
    2. Increased OX40 expression is associated with gastric cancer. PMID: 29529339
    3. this study demonstrates that cSCCs contain an abundance of Tregs which can suppress tumoral effector T cell function and that activation of the costimulatory receptor OX40 enhances tumoral T cell responses. PMID: 27034329
    4. OX40 expression on T cells was positively associated with obesity in humans. PMID: 28612217
    5. Metabolically active CD4+ T cells expressing Glut1 and OX40 preferentially harbor HIV during in vitro infection. PMID: 28892135
    6. this study investigated whether CD134 is preferentially expressed on CD4 T cells in drug-induced hypersensitivity syndrome . PMID: 27174092
    7. blocking of both OX-40L and 4-1BBL reversed radiation-enhanced T-cell killing of human tumor targets as well as T-cell survival and activation. PMID: 26872462
    8. Low OX40 expression is associated with colorectal cancer. PMID: 26439988
    9. OX40 and its ligand are co stimulators for T lymphocytes. PMID: 26755473
    10. These studies provide the first direct evidence that ligation of tumour necrosis factor superfamily members and their cognate receptors is important for the control of viral lytic replication. PMID: 26467721
    11. Malaria patients and Plasmodium-infected rodents exhibit enhanced expression of the co-stimulatory receptor OX40 on CD4 T cells, which is abrogated following coordinate PD-1 co-inhibitory pathways, which are also upregulated during malaria. PMID: 25891357
    12. Identified two key amino acid residues within CD134 that are required for its interaction with herpesvirus 6B (HHV-6B) and for HHV-6B entry into cells. One of the residues (K79) allows access of the HHV-6B ligand to CD134. PMID: 26202244
    13. TL1A increases expression of CD25, LFA-1, CD134 and CD154, and induces IL-22 and GM-CSF production from effector CD4 T-cells PMID: 25148371
    14. High expression of OX40 is associated with type 1 diabetes. PMID: 24797972
    15. A cysteine-rich domain of CD134 that is critical for binding to the HHV-6B glycoprotein gH/gL/gQ1/gQ2 complex and HHV-6B infection. PMID: 25008928
    16. cirrhotic and hepatocellular carcinoma fragments moderately and highly infiltrated by Tregs, respectively, expressing OX40 PMID: 24756990
    17. data show that Ag-specific CD4(+) CD25(+) CD134(+) CD39(+) T cells are highly enriched for Treg cells, form a large component of recall responses and maintain a Treg-cell-like phenotype upon in vitro expansion. PMID: 24752698
    18. expression is associated with breast cancer in a stage dependent manner PMID: 23502335
    19. OX40 signals regulate CD8 T cell survival at least in part through maintaining expression of the anti-apoptotic molecule A1 PMID: 23936461
    20. Hyperactivation of the Akt pathway in Teff cells from children with lupus nephritis is associated with reduced induction of TRAF6 and up-regulation of OX40, which may cause Teff cell resistance to Treg cell-mediated suppression. PMID: 23896866
    21. This study identified OX40 as a key molecule and biomarker for rapid progression of HTLV-1-associated myelopathy/tropical spastic paraparesis. PMID: 23651542
    22. CD134 is a cellular receptor specific for human herpesvirus-6B entry. PMID: 23674671
    23. Head and neck cancer patients have decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB. PMID: 22204816
    24. CD137 activity is directly proportional to colorectal cancer stage. Surgical resection of the tumor results in increased CD134 and CD137 expression PMID: 22343199
    25. We show that the inflammatory and cytotoxic function of CD4(+)CD28(null) T cells can be inhibited by blocking OX40 and 4-1BB costimulatory receptors. PMID: 22282196
    26. PAPP-A level was significantly related to soluble and membrane-bound OX40L in patients with ACS. PMID: 21111564
    27. Compared with control group, the expression of OX40 and Bcl-2 was significantly higher in allergic rhinitis. PMID: 19253527
    28. Transgenic OX40 forms a signaling complex in T cells that contains phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB). PMID: 21289304
    29. High OX40 expression may be associated with malignant transformation, progression, invasion and metastasis in breast cancer biology. PMID: 20634005
    30. Possible proinflammatory effects of OX40L on the pathogenesis of atherosclerois. PMID: 21086790
    31. This study has shown that activation of OX40 induces CCL20 expression in the presence of antigen stimulation. PMID: 20400327
    32. The rs2298212G/A polymorphism in OX40 gene may be associated with the severity of coronary atherosclerotic disease. PMID: 20376799
    33. Data suggest the role of Perforin + cytotoxic T lymphocytes and CD134+ cells in the pathogenesis of autoimmunity of SLE. PMID: 20306696
    34. Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. PMID: 12296857
    35. CD134 positive cells are identified within inflammatory lesions of active multiple sclerosis (MS), acute MS and chronic active MS as well as in acute disseminated leukoencephalitis patients. PMID: 14644025
    36. Mutagenesis showed that Asp60 and Asp62 are required for interaction with FIV, and modeling studies localized these two residues to the outer edge of domain 1 PMID: 15592478
    37. The expression of CD134 was markedly higher, compared to CD137, both on the day of the surgery and ten days after colorectal cancer surgery. PMID: 15638367
    38. Deficiencies in OX40 and CD30 signals were additive, secondary Ab responses were ablated.OX40/CD30 double-knockout OTII transgenic T cells fail to survive compared with normal T cells when cocultured with CD4(+)CD3(-) cells in vitro. PMID: 15778343
    39. Decrease in OX40 expression posttransplant includes the defective reconstitution of Treg cells, and the active inhibition of gene transcription by cyclosporine. PMID: 15808546
    40. stimulation of OX40/4-1BB rendered cells sensitive to apoptosis induced by TNF-alpha and reduced activation of NF-kappaB. OX40/4-1BB stimulation repressed the mitogen response in activated CD25+CD4+ T cells and preactivated CD8+ T cells PMID: 15941918
    41. CD3+ T lymphocytes co-expressing CD134 and CD137 antigens on peripheral blood revealed an increased percentages of OX-40/CD137 positive cells in patients with Graves' disease (p<0.025) compared to the controls. PMID: 16232366
    42. The relevance of these findings is supported by the vital functions fulfilled by OX40 in mammals as reflected by the high level of evolutionary conservation. PMID: 16329997
    43. The coexpression of CD25 and the costimulatory molecule CD134 on memory T-cells provides a novel marker for type 1 diabetes-associated T-cell immunity. PMID: 16380476
    44. OX40 ligation on CD4(+) T cells represents a potentially novel immunotherapeutic strategy that should be investigated to treat and prevent persistent virus infections, such as HIV-1 infection. PMID: 16456009
    45. OX40 is induced transiently on CD8(+) T cells upon activation and its signals contribute to both clonal expansion and functional reinforcement PMID: 16750861
    46. In the present study we found that costimulation via OX40 and TNF-R in OX40-expressing HIV-1-infected T cell lines leads to a marked reduction of HIV-1 production associated with rapid cell death. PMID: 18327975
    47. The expression of OX40 on CD4+ T cells in sentinel lymph nodes draining primary melanomas decreased withe more advanced tumor features, suggesting an immunosuppressive effect. PMID: 18374895
    48. Activity of OX40 ligand is enhanced by oligomerization and cell surface immobilization. PMID: 18397322
    49. the frequency of the most frequent haplotype, C-C-A-A, was significantly lower and that of the second most frequent, C-T-G-A, was significantly higher in hypertensive subjects than in controls. This difference was observed only in female patients PMID: 18398332
    50. These data offer a novel approach for UCB Treg expansion using aAPCs, including those coexpressing OX40L or 4-1BBL. PMID: 18645038

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Immunodeficiency 16 (IMD16)
  • 亞細(xì)胞定位：
    Membrane; Single-pass type I membrane protein.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 11918

    OMIM: 600315

    KEGG: hsa:7293

    STRING: 9606.ENSP00000368538

    UniGene: Hs.129780



×
生命科學(xué)計算平臺